NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Journal of Clinical Investigation

Volumn 112, Issue 3, 2003, Pages 440-449

  Eriksen, Jason L ^a   Sagi, Sarah A ^b   Smith, Tawnya E ^a   Weggen, Sascha ^b   Das, Pritam ^a   McLendon, D C ^a   Ozols, Victor V ^a   Jessing, Kevin W ^c   Zavitz, Kenton H ^c   Koo, Edward H ^b   Golde, Todd E ^a,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Myriad Pharmaceuticals Inc   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-42]; DAPSONE; DICLOFENAC; DIFLUNISAL; DIMETHYL SULFOXIDE; ETODOLAC; FENBUFEN; FENOPROFEN; FLURBIPROFEN; GAMMA SECRETASE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; MEFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN SYNTHASE; SULINDAC; SUPROFEN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; PEPTIDE FRAGMENT; PROTEINASE; PROTEINASE INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CELL CULTURE; CELL STRAIN; CELL STRAIN H4; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENANTIOMER; ENZYME ASSAY; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RACEMIC MIXTURE; RISK; RISK REDUCTION; SIDE EFFECT; TRANSGENIC MOUSE; ANIMAL; BRAIN; CELL LINE; CHEMISTRY; FEMALE; METABOLISM; MOUSE; STEREOISOMERISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; BRAIN; CELL LINE; ENDOPEPTIDASES; FEMALE; FLURBIPROFEN; HUMANS; MECLOFENAMIC ACID; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; STEREOISOMERISM;

EID: 85047691727     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI18162     Document Type: Article

References (46)

1. Selkoe, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
2. Hardy,J.A., and Higgins, G.A. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science. 256:184-185.
3. Golde, T.E., Eckman, C.B., and Younkin, S.G. 2000. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta. 1502:172-187.
4. Younkin, S.G. 1998. The role of A beta 42 in Alzheimer's disease. J. Physiol. (Paris). 92:289-292.
5. Scheuner, D., et al. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:864-870.
6. Duff, K., et al. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:710-713.
7. Games, D., et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:523-527.
8. Akiyama, H., et al. 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:383-421.
9. Wyss-Coray, T., et al. 2002. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99:10837-10842.
10. Aisen, PS. 1997. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology. 43:143-149.
11. McGeer, P.L., Schulzer, M., and McGeer, E.G. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:425-432.
12. in t'Veld, B.A., et al. 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345:1515-1521.
13. Stewart, W.F., Kawas, C., Corrada, M., and Metter, E.J. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:626-632.
14. Zandi, P.P., et al. 2002. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 59:880-886.
15. Weggen, S., et al. 2001. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature. 414:212-216.
16. Geisslinger, G., Lotsch, J., Menzel, S., Kobal, G., and Brune, K. 1994. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br. J. Clin. Pharmacol. 37:392-394.
17. Wechter, W.J., et al. 2000. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res. 60:2203-2208.
18. Wechter, W.J., et al. 2000. Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci. 66:745-753.
19. Murphy, M.P., et al. 2000. Presenilin 1 regulates pharmacologically distinct gamma-secretase activities. Implications for the role of presenilin in gamma-secretase cleavage. J. Biol. Chem. 275:26277-26284.
20. Wang, R., Sweeney, D., Gandy, S.E., and Sisodia, S.S. 1996. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 271:31894-31902.
21. McLendon, C., et al. 2000. Cell-free assays for γ-secretase activity. FASEB J. 14:2383-2386.
22. Wahrle, S., et al. 2002. Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9:11-23.
23. Hsiao, K., et al. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
24. Kawarabayashi, T., et al. 2001. Age-dependent changes in brain, CSF, and plasma amyloid protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:372-381.
25. Suzuki, N., et al. 1994. An increased percentage of long amyloid β protein is secreted by familial amyloid β protein precursor (βAPP717) mutants. Science. 264:1336-1340.
26. Takasugi, N., et al. 2003. The role of presenilin cofactors in the γ-secretase complex. Nature. 422:438-441.
27. Edbauer, D., et al. 2003. Reconstitution of gamma-secretase activity. Nat. Cell Biol. 7:7.
28. Wolfe, M.S., et al. 1999. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 398:513-517.
29. Lim, G.P., et al. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:5709-5714.
30. Ritschel, W.A., and Kerns, G.L. 1999. Handbook of basic pharmacokinetics... including clinical applications. J.I. Graubart, editor. American Pharmaceutical Association. Washington, DC, USA. 563 pp.
31. Wechter, W.J., Bigornia, A.E., Murray, E.D., Jr., and Jee, W.S. 1994. Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. Chirality. 6:457-459.
32. Abdel-Halim, M.S., Sjoquist, B., and Anggard, E. 1978. Inhibition of prostaglandin synthesis in rat brain. Acta Pharmacol. Toxicol. (Copenh.). 43:266-272.
33. Golde, T.E. 2003. Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest. 111:11-18.
34. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G.G., and Siegel, G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57:1439-1443.
35. Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S., and Drachman, D.A. 2000. Statins and the risk of dementia. Lancet. 356:1627-1631.
36. Scharf, S., Mander, A., Ugoni, A., Vajda, F., and Christophidis, N. 1999. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 53:197-201.
37. Rogers, J., et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1609-1611.
38. Marnett, L.J., Kalgutkar, A.S. 1999. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol. Sci. 20:465-469.
39. Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B., and Landreth, G.E. 2000. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J. Neurosci. 20:558-567.
40. Heneka, M.T., et al. 1999. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100:156-168.
41. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M., and Holtzman, D.M. 2002. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 295:2264-2267.
42. DeMattos, R.B., et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850-8855.
43. Morihara, T., Chu, T., Ubeda, O., Beech, W., and Cole, GM. 2002. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem. 83:1009-1012.
44. Jantzen, P.T., et al. 2002. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22:2246-2254.
45. Tegeder, I., et al. 2001. Inhibition of NF-κB and AP-1 activation by R- and S-flurbiprofen. FASEB J. 15:2-4.
46. Murray, E.D., Jr., et al. 2000. Phase I single-dose pharmacokinetics and lack of enantiomer bioinversion of E-7869 (R-flurbiprofen). Clin. Pharmacol. Ther. 67:103.